These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 11880864

  • 1. Effect of bicalutamide therapy on prolactin response to L-dopa in metastatic prostate cancer patients.
    Lissoni P, Malugani F, Casu M, Bukovec R, Egardi R, Bordin V, Fumagalli E, Mengo S, Gardani G.
    Neuro Endocrinol Lett; 2002 Feb; 23(1):61-3. PubMed ID: 11880864
    [Abstract] [Full Text] [Related]

  • 2. A phase II study of tamoxifen in hormone-resistant metastatic prostate cancer: possible relation with prolactin secretion.
    Lissoni P, Vigano P, Vaghi M, Frontini L, Giuberti C, Manganini V, Casu M, Brivio F, Niespolo R, Strada G.
    Anticancer Res; 2005 Feb; 25(5):3597-9. PubMed ID: 16101186
    [Abstract] [Full Text] [Related]

  • 3. A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
    Davis NB, Ryan CW, Stadler WM, Vogelzang NJ.
    BJU Int; 2005 Oct; 96(6):787-90. PubMed ID: 16153201
    [Abstract] [Full Text] [Related]

  • 4. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T, Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group.
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [Abstract] [Full Text] [Related]

  • 5. Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer.
    Boccardo F, Rubagotti A, Conti G, Potenzoni D, Manganelli A, Del Monaco D.
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):415-20. PubMed ID: 15838655
    [Abstract] [Full Text] [Related]

  • 6. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade.
    Schellhammer PF, Venner P, Haas GP, Small EJ, Nieh PT, Seabaugh DR, Patterson AL, Klein E, Wajsman Z, Furr B, Chen Y, Kolvenbag GJ.
    J Urol; 1997 May; 157(5):1731-5. PubMed ID: 9112515
    [Abstract] [Full Text] [Related]

  • 7. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.
    Tyrrell CJ, Iversen P, Tammela T, Anderson J, Björk T, Kaisary AV, Morris T.
    BJU Int; 2006 Sep; 98(3):563-72. PubMed ID: 16771791
    [Abstract] [Full Text] [Related]

  • 8. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.
    McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP, Casodex Early Prostate Cancer Trialists' Group.
    BJU Int; 2006 Feb; 97(2):247-54. PubMed ID: 16430622
    [Abstract] [Full Text] [Related]

  • 9. The patient's choice of androgen-deprivation therapy in locally advanced prostate cancer: bicalutamide, a gonadotrophin-releasing hormone analogue or orchidectomy.
    Nyman CR, Andersen JT, Lodding P, Sandin T, Varenhorst E.
    BJU Int; 2005 Nov; 96(7):1014-8. PubMed ID: 16225519
    [Abstract] [Full Text] [Related]

  • 10. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
    Sartor O, Gomella LG, Gagnier P, Melich K, Dann R.
    Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
    [Abstract] [Full Text] [Related]

  • 11. [The role of bicalutamide in the treatment of prostate cancer].
    Stav SY, Segal G.
    Harefuah; 2002 Apr; 141(4):379-83, 408, 407. PubMed ID: 12017896
    [Abstract] [Full Text] [Related]

  • 12. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
    Nishimura K, Arichi N, Tokugawa S, Yoshioka I, Kishikawa H, Ichikawa Y.
    Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
    [Abstract] [Full Text] [Related]

  • 13. Paradoxical stimulation of prolactin secretion by L-dopa in metastatic prostate cancer and its possible role in prostate-cancer-related hyperprolactinemia.
    Lissoni P, Mandalà M, Rovelli F, Casu M, Rocco F, Tancini G, Scardino E.
    Eur Urol; 2000 May; 37(5):569-72. PubMed ID: 10765095
    [Abstract] [Full Text] [Related]

  • 14. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J, Orsola A, Planas J, Trilla E, Raventós CX, Cecchini L, Catalán R.
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [Abstract] [Full Text] [Related]

  • 15. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
    Fujii Y, Kawakami S, Masuda H, Kobayashi T, Hyochi N, Kageyama Y, Kihara K.
    BJU Int; 2006 Jun; 97(6):1184-9. PubMed ID: 16686709
    [Abstract] [Full Text] [Related]

  • 16. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H, Hara I, Eto H.
    BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
    [Abstract] [Full Text] [Related]

  • 17. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.
    Yoshida T, Kinoshita H, Segawa T, Nakamura E, Inoue T, Shimizu Y, Kamoto T, Ogawa O.
    Cancer Res; 2005 Nov 01; 65(21):9611-6. PubMed ID: 16266977
    [Abstract] [Full Text] [Related]

  • 18. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
    Sciarra A, Di Silverio F.
    Urology; 2004 Mar 01; 63(3):523-7. PubMed ID: 15028450
    [Abstract] [Full Text] [Related]

  • 19. Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer.
    Gravina GL, Festuccia C, Galatioto GP, Muzi P, Angelucci A, Ronchi P, Costa AM, Bologna M, Vicentini C.
    Urology; 2007 Oct 01; 70(4):728-33. PubMed ID: 17991545
    [Abstract] [Full Text] [Related]

  • 20. Pathological changes of high-grade prostatic intraepithelial neoplasia and prostate cancer after monotherapy with bicalutamide 150 mg.
    Scattoni V, Montironi R, Mazzucchelli R, Freschi M, Nava L, Losa A, Terrone C, Scarpa RM, Montorsi F, Pappagallo G, Rigatti P.
    BJU Int; 2006 Jul 01; 98(1):54-8. PubMed ID: 16831143
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.